Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China

SHANGHAI - UK-listed Chinese healthcare company Chi-Med is expected to double its current revenues of $111 million in the next five years, backed by rapid growth in traditional Chinese medicine and consumer products, U.S. investment banking firm Piper Jaffray said in an Aug. 4 research note